14,240 Shares in Scholar Rock Holding Corporation $SRRK Bought by Dynamic Technology Lab Private Ltd

Key Points

• Dynamic Technology Lab Private Ltd has acquired 14,240 shares of Scholar Rock Holding Corporation, valued at approximately $458,000, as reported in its Form 13F filing.
• Scholar Rock Holding Corporation's recent earnings report revealed an EPS of ($0.98), missing the consensus estimate by ($0.32).
• Investors exhibit strong interest in Scholar Rock, with a consensus rating of "Buy" and a price target of $45.75 from analysts.

Dynamic Technology Lab Private Ltd acquired a new stake in shares of Scholar Rock Holding Corporation (NASDAQ:SRRK - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 14,240 shares of the company's stock, valued at approximately $458,000.

A number of other large investors also recently bought and sold shares of the stock. Lord Abbett & CO. LLC raised its stake in shares of Scholar Rock by 86.2% in the 1st quarter. Lord Abbett & CO. LLC now owns 877,374 shares of the company's stock valued at $28,207,000 after acquiring an additional 406,074 shares during the period. Northern Trust Corp raised its stake in shares of Scholar Rock by 2.5% in the 1st quarter. Northern Trust Corp now owns 765,280 shares of the company's stock valued at $24,604,000 after acquiring an additional 18,753 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Scholar Rock by 42.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 135,231 shares of the company's stock valued at $5,845,000 after acquiring an additional 40,436 shares during the period. GAMMA Investing LLC raised its stake in shares of Scholar Rock by 3,824.9% in the 1st quarter. GAMMA Investing LLC now owns 30,928 shares of the company's stock valued at $962,000 after acquiring an additional 30,140 shares during the period. Finally, Nuveen LLC purchased a new position in shares of Scholar Rock in the 1st quarter valued at $12,775,000. Hedge funds and other institutional investors own 91.08% of the company's stock.

Insider Activity at Scholar Rock

In other news, Director Jeffrey S. Flier sold 20,316 shares of the stock in a transaction on Monday, June 23rd. The shares were sold at an average price of $32.24, for a total transaction of $654,987.84. Following the transaction, the director owned 24,070 shares in the company, valued at $776,016.80. This represents a 45.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Mo Qatanani sold 24,066 shares of the stock in a transaction on Tuesday, July 8th. The stock was sold at an average price of $34.44, for a total transaction of $828,833.04. Following the transaction, the insider owned 115,495 shares in the company, valued at approximately $3,977,647.80. This trade represents a 17.24% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 66,654 shares of company stock worth $2,299,310. Company insiders own 13.30% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on SRRK shares. Raymond James Financial set a $53.00 price target on shares of Scholar Rock and gave the company a "strong-buy" rating in a report on Wednesday, July 30th. Wedbush reissued an "outperform" rating and set a $50.00 price objective on shares of Scholar Rock in a report on Wednesday, June 18th. Cantor Fitzgerald began coverage on shares of Scholar Rock in a report on Thursday, July 17th. They set an "overweight" rating for the company. Lifesci Capital raised shares of Scholar Rock to a "strong-buy" rating in a report on Tuesday, June 3rd. Finally, Leerink Partners initiated coverage on shares of Scholar Rock in a report on Monday. They set an "outperform" rating and a $51.00 price objective for the company. Three research analysts have rated the stock with a Strong Buy rating and ten have issued a Buy rating to the company. According to MarketBeat.com, the company has an average rating of "Buy" and an average target price of $46.20.

Scholar Rock Trading Up 3.2%

Shares of SRRK stock traded up $1.03 during trading hours on Wednesday, reaching $33.37. 252,041 shares of the stock traded hands, compared to its average volume of 1,304,457. Scholar Rock Holding Corporation has a 1-year low of $6.76 and a 1-year high of $46.98. The business has a fifty day moving average price of $35.04 and a 200 day moving average price of $33.19. The company has a quick ratio of 6.33, a current ratio of 6.33 and a debt-to-equity ratio of 0.21. The firm has a market capitalization of $3.21 billion, a PE ratio of -11.53 and a beta of 0.36.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.32). During the same quarter in the previous year, the business posted ($0.60) EPS. On average, equities research analysts forecast that Scholar Rock Holding Corporation will post -2.42 EPS for the current year.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.